BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 26166238)

  • 1. Infusion Therapies and Development of Impulse Control Disorders in Advanced Parkinson Disease: Clinical Experience After 3 Years' Follow-up.
    Todorova A; Samuel M; Brown RG; Chaudhuri KR
    Clin Neuropharmacol; 2015; 38(4):132-4. PubMed ID: 26166238
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EuroInf: a multicenter comparative observational study of apomorphine and levodopa infusion in Parkinson's disease.
    Martinez-Martin P; Reddy P; Katzenschlager R; Antonini A; Todorova A; Odin P; Henriksen T; Martin A; Calandrella D; Rizos A; Bryndum N; Glad A; Dafsari HS; Timmermann L; Ebersbach G; Kramberger MG; Samuel M; Wenzel K; Tomantschger V; Storch A; Reichmann H; Pirtosek Z; Trost M; Svenningsson P; Palhagen S; Volkmann J; Chaudhuri KR
    Mov Disord; 2015 Apr; 30(4):510-6. PubMed ID: 25382161
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improvement of impulse control disorders associated with levodopa-carbidopa intestinal gel treatment in advanced Parkinson's disease.
    Catalan MJ; Molina-Arjona JA; Mir P; Cubo E; Arbelo JM; Martinez-Martin P;
    J Neurol; 2018 Jun; 265(6):1279-1287. PubMed ID: 29557989
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Impulse control disorders in Parkinson's disease: A cohort of 35 patients].
    Carrière N; Kreisler A; Dujardin K; Destée A; Defebvre L
    Rev Neurol (Paris); 2012 Feb; 168(2):143-51. PubMed ID: 22129474
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proficient motor impulse control in Parkinson disease patients with impulsive and compulsive behaviors.
    Claassen DO; van den Wildenberg WP; Harrison MB; van Wouwe NC; Kanoff K; Neimat JS; Wylie SA
    Pharmacol Biochem Behav; 2015 Feb; 129():19-25. PubMed ID: 25459105
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Longitudinal analysis of impulse control disorders in Parkinson disease.
    Corvol JC; Artaud F; Cormier-Dequaire F; Rascol O; Durif F; Derkinderen P; Marques AR; Bourdain F; Brandel JP; Pico F; Lacomblez L; Bonnet C; Brefel-Courbon C; Ory-Magne F; Grabli D; Klebe S; Mangone G; You H; Mesnage V; Lee PC; Brice A; Vidailhet M; Elbaz A;
    Neurology; 2018 Jul; 91(3):e189-e201. PubMed ID: 29925549
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impulse control and related disorders in Parkinson's disease.
    Weintraub D; Nirenberg MJ
    Neurodegener Dis; 2013; 11(2):63-71. PubMed ID: 23038208
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impulse control disorders in Parkinson's disease patients with RLS: a cross sectional-study.
    Marques A; Figorilli M; Pereira B; Derost P; Debilly B; Beudin P; Vidal T; Durif F; Fantini ML
    Sleep Med; 2018 Aug; 48():148-154. PubMed ID: 29913341
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long term follow-up of Parkinson's disease patients with impulse control disorders.
    Sohtaoğlu M; Demiray DY; Kenangil G; Ozekmekçi S; Erginöz E
    Parkinsonism Relat Disord; 2010 Jun; 16(5):334-7. PubMed ID: 20223696
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognosis of impulse control disorders in Parkinson's disease: a prospective controlled study.
    Wirth T; Goetsch T; Corvol JC; Roze E; Mariani LL; Vidailhet M; Grabli D; Mallet L; Pelissolo A; Rascol O; Brefel-Courbon C; Ory-Magne F; Arbus C; Bekadar S; Krystkowiak P; Marques A; Llorca M; Krack P; Castrioto A; Fraix V; Maltete D; Defebvre L; Kreisler A; Houeto JL; Tranchant C; Meyer N; Anheim M
    J Neurol; 2024 May; 271(5):2412-2422. PubMed ID: 38214756
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Continuous subcutaneous apomorphine monotherapy in Parkinson's disease.
    Papuć E; Trzciniecka O; Rejdak K
    Ann Agric Environ Med; 2019 Mar; 26(1):133-137. PubMed ID: 30922043
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term cognitive follow-up of Parkinson's disease patients with impulse control disorders.
    Siri C; Cilia R; Reali E; Pozzi B; Cereda E; Colombo A; Meucci N; Canesi M; Zecchinelli AL; Tesei S; Mariani CB; Sacilotto G; Zini M; Pezzoli G
    Mov Disord; 2015 Apr; 30(5):696-704. PubMed ID: 25757654
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Impulsive-compulsive syndrome in Parkinson's disease].
    Nikitina AV; Fedorova NV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2013; 113(7 Pt 2):32-8. PubMed ID: 23994929
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impulse control disorders in Parkinson disease: A cross-sectional study in Morocco.
    El Otmani H; Mouni FZ; Abdulhakeem Z; Attar Z; Rashad L; Saali I; El Moutawakil B; Rafai MA; Slassi I; Nadifi S
    Rev Neurol (Paris); 2019 Apr; 175(4):233-237. PubMed ID: 30935674
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Continuous subcutaneous apomorphine infusion in advanced Parkinson's disease: 10-year experience with 230 patients.
    Sesar Á; Fernández-Pajarín G; Ares B; Rivas MT; Castro A
    J Neurol; 2017 May; 264(5):946-954. PubMed ID: 28364292
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non-motor symptom burden in patients with Parkinson's disease with impulse control disorders and compulsive behaviours: results from the COPPADIS cohort.
    Jesús S; Labrador-Espinosa MA; Adarmes AD; Méndel-Del Barrio C; Martínez-Castrillo JC; Alonso-Cánovas A; Sánchez Alonso P; Novo-Ponte S; Alonso-Losada MG; López Ariztegui N; Segundo Rodríguez JC; Morales MI; Gastón I; Lacruz Bescos F; Clavero Ibarra P; Kulisevsky J; Pagonabarraga J; Pascual-Sedano B; Martínez-Martín P; Santos-García D; Mir P;
    Sci Rep; 2020 Oct; 10(1):16893. PubMed ID: 33037247
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Motor features and response to oral levodopa in patients with Parkinson's disease under continuous dopaminergic infusion or deep brain stimulation.
    Elia AE; Dollenz C; Soliveri P; Albanese A
    Eur J Neurol; 2012 Jan; 19(1):76-83. PubMed ID: 21645174
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-life benefits of intrajejunal levodopa infusion therapy in four patients with the parkinsonian variant of progressive supranuclear palsy: A 1-year follow-up data report.
    Metta V; Chaudhuri KR; Leta V; Mridula KR; Koduri C; Deepak S; Kalpala R; Reddy N; Chung-Faye G; Borgohain R
    Brain Behav; 2022 Sep; 12(9):e2547. PubMed ID: 35943202
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Levodopa infusion improves impulsivity and dopamine dysregulation syndrome in Parkinson's disease.
    Catalán MJ; de Pablo-Fernández E; Villanueva C; Fernández-Diez S; Lapeña-Montero T; García-Ramos R; López-Valdés E
    Mov Disord; 2013 Dec; 28(14):2007-10. PubMed ID: 24123193
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intrajejunal levodopa infusion therapy for Parkinson's disease: practical and pragmatic tips for successful maintenance of therapy.
    Titova N; Ray Chaudhuri K
    Expert Rev Neurother; 2017 Jun; 17(6):529-537. PubMed ID: 28406336
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.